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BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas
harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying
melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first
selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared
to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3). The study results showed a relative reduction of
63 % in risk of death and 74 % in risk of tumor progression. Considering all trials so far completed, median overall survival
reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment.
Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been
demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA
therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that
continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease
progression (PD). Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall
survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients
who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical
phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor
mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective
inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might
be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under
evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors
were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous
squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors.
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BRAF is a serine/threonine protein kinase, encoded on
chromosome 7q34, that activates the MAP kinase/ERK-
signaling pathway. BRAF is the family member most easily
activated by Ras [1,2]. In addition, the basal kinase activity
of BRAF is higher than that of other family members [3,4].
This provides a potential rationale for the frequent muta-
tional activation of BRAF observed in human tumors [5].* Correspondence: paolo.ascierto@gmail.com
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reproduction in any medium, provided the orIn fact, approximately 50 % of melanomas harbor activat-
ing BRAF mutations. Among the BRAF mutations observed
in melanoma, over 90 % are at codon 600, and among these,
over 90 % are a single nucleotide mutation resulting in sub-
stitution of glutamic acid for valine (BRAFV600E: nucleo-
tide 1799 T>A; codon GTG>GAG). The second most
common mutation is BRAFV600K substituting lysine for
valine, that represents 5-6 % (GTG>AAG), followed by
BRAFV600R (GTG>AGG), an infrequent two-nucleotide
variation of the predominant mutation, BRAF V600 ′E2′
(GTG>GAA), and BRAF V600D (GTG>GAT) [6]. The
prevalence of BRAFV600K has been reported as higher in
some populations [7].
In melanoma, BRAF mutation is most common in
patients whose tumors arise on skin without chronicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in melanomas arising from mucosal and acral sites [8].
A major advance of the past few years was the discovery
that RAF kinases can homo- and heterodimerize [9,10],
and that, in fact, the structure of an active RAF kinase is
that of a side-to-side dimer in which only one partner
must have catalytic activity [11]. Dimerization is enhanced
by Ras [12] and is subject to negative feedback regulation
by ERK [10,13].
Several RAF mutations have been implicated in the in-
duction of genomic instability, driving the proliferation of
cancer cells with the highest frequency in melanoma. For
instance, mutated BRAF signals as a monomer, independ-
ent of upstream growth stimuli. The most frequent BRAF
mutation, BRAFV600E, causes constitutive activation of
the kinase as well as insensitivity to negative feedback
mechanisms [5,14].
BRAFV600E has been implicated in different mechanisms
of melanoma progression, and principally the activation of
the downstream MEK/ERK pathway, evasion of senescence
and apoptosis, unchecked replicative potential, angiogenesis
(through MEK-dependent activation of HIF-1α and VEGF),
tissue invasion and metastasis (via upregulation of several
proteins involved in migration, integrin signaling, cell
contractility, tumor- and microenvironment-derived
interleukin-8), as well as the evasion of immune re-
sponse [15].
No clear differences in prognosis (time from primary
diagnosis to distant metastasis) were noted between
BRAF-mutated versus wild-type melanomas. Features of
the antecedent primary melanoma significantly associated
with a BRAF mutation (P< 0.05) were the superficial
spreading and nodular histopathological subtypes, the pres-
ence of mitoses, the presence of a single or occult primary
melanoma, a truncal location and age at diagnosis of the
primary tumor (≤50 years) [7].
The discovery of the genetic underpinnings of melanoma
and their characterization have exposed potential targets
for therapy, BRAF mutations being principal among them
(Figure 1) [16].
BRAF inhibition: previous experience
Sorafenib, a non-selective BRAF broad-spectrum kinase
inhibitor with a bi-aryl urea structure, was originally
developed in combination with carboplatin and taxol
against lung cancer. Activity against melanoma was
demonstrated in phase I studies, and so it was further
developed for this indication in combination with the
unusual combination of carboplatin and paclitaxel. Because
of response rates over 30 % in phase II studies, its develop-
ment was pursued into large phase III trials, but eventually
it failed both in second- and first-line trials [17]. In fact, the
addition of sorafenib to carboplatin and paclitaxel (CP) did
not improve any of the relevant end points over placeboplus CP in the second-line setting for patients with
advanced melanoma [18].
Studies of sorafenib indicate that it lacks selectivity
and potency for RAF, and that it is a highly potent inhibi-
tor of VEGFR2, VEGFR3, and several other kinases [19].
Sorafenib ultimately demonstrated clinical activity in renal
cell carcinoma (RCC) and hepatocellular cancer and is
now approved for use in these indications. These findings
suggest that the activity of sorafenib in RCC is likely attrib-
utable to its anti-angiogenic properties and that inhibition
of RAF contributes little if at all to its clinical efficacy in
this disease.
Vemurafenib: phase I and II results
In phase III studies, dacarbazine, the only chemotherapeutic
agent approved by the U.S. Food and Drug Administration
(FDA) for the treatment of metastatic melanoma, was asso-
ciated with a response rate of 7 to 12 % and a median over-
all survival of 5.6 to 7.8 months after the initiation of
treatment.
Recently a selective and potent inhibitor of oncogenic
mutant BRAF [20], vemurafenib (PLX4032/RG7204/
RO5185426), gave positive results in phase I [21] and
phase II trials (Figure 2) [22].
The phase I study was a multicenter, 55-solid cancer
patients dose-escalation trial followed by a 32-melanoma
patients extension phase involving the maximum dose
that could be administered without adverse effects (the
recommended phase II dose). Vemurafenib was adminis-
tered at a starting dose of 160 mg daily and was generally
well tolerated with no dose-limiting toxicity until the
720 mg twice-daily dose level was initiated. This trial
demonstrated that vemurafenib has very impressive single-
agent clinical activity, with unprecedented objective re-
sponse rates (complete plus partial tumor regression) in
about 81 % and a confirmed response rate in about 56%of
patients who had melanoma with the BRAFV600E muta-
tion; the study also showed a clear impact on PFS
>7 months and established the maximum tolerated dose
to be 960 mg twice-daily. Responses were observed at all
sites of disease, including the bone, liver and small bowel.
During the dose escalation phase, responses were also
observed in patients who were receiving doses below the
recommended one [21].
The phase II trial involving patients who had received
previous treatment for melanoma with the BRAFV600E
mutation investigated the efficacy of vemurafenib with
respect to overall response rate (primary end-point,
defined as percentage of treated patients with a tumor
response), duration of response and overall survival. The
study enrolled 132 patients who were administered
vemurafenib at a dose of 960 mg orally twice-daily (until
the development of unacceptable toxic effects or disease
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Figure 1 Oncogenic BRAF signaling pathway. RTK: receptor tyrosine kinase.
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and a median overall survival of 15.9 months, an unpre-
cedented outcome in melanoma patients.
The overall survival rate at 6 months was 77 % (95 % CI,
70 to 85), 58 % at 12 months (95 % CI, 49 to 67) and esti-
mated to be 43 % at 18 months (95 % CI, 33 to 53). During
the follow-up period (median was 12.9 months, range 0.6
to 20.1), 24 % patients received ipilimumab after they had
disease progression while receiving vemurafenib. In an un-
planned post hoc analysis, median overall survivalFigure 2 The structural formula of vemurafenib.remained at 15.9 months (95 % CI, 8.0 to not reached)
even when these ipilimumab-treated patients were not
included [22].Vemurafenib: the BRIM-3 results
The 2-arm randomized phase III trial in treatment-naïve
patients (BRIM-3) compared vemurafenib, 960 mg orally
twice-daily, to dacarbazine chemotherapy, 1,000 mg/m2
administered every 3 weeks. Progression-free survival (PFS)
and overall survival were co-primary end-points in this 675
patients-trial on unresectable, previously untreated stage
IIIC or stage IV metastatic melanoma with the BRAFV600E
mutation. The study results were associated with a relative
reduction of 63 % in the risk of death and of 74 % in the risk
of tumor progression in patients. To date, after a longer fol-
low-up (data cut-off 3rd October 2011) the median OS for
vemurafenib arm is of 13.2 months compared to 9.9 months
in the dacarbazine arm [23]. Notably, 38 % of patients
required dose reduction in the vemurafenib arm.
Common adverse events associated with vemurafenib
were arthralgia, rash, fatigue, alopecia, keratoacanthoma
or cutaneous squamous-cell carcinoma (cSCC), photo-
sensitivity, nausea and diarrhea.
Vemurafenib was the first personalized compound
which demonstrated an improvement in PFS and OS
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mutation [24].
U.S. and European approval
On August 17th, 2011, the U.S. Food and Drug Adminis-
tration (FDA) approved vemurafenib tablets for unresect-
able or metastatic melanoma with the BRAFV600E
mutation as detected by a concurrently FDA-approved test.
The FDA has stamped an early approval on vemurafenib
two months ahead of its PDUFA date. It was in fact
reviewed under the FDA’s priority review program that
provides for an expedited six-month review of drugs that
may offer major advances in treatment or that provide a
treatment when no adequate therapy exists.
On December 15th, 2011, the European Medicine Agency
(EMA)’s Committee for Human Medicinal Products
(CHMP) recommended the granting of a marketing
authorization for vemurafenib to treat patients with meta-
static or unresectable melanoma and the BRAFV600 muta-
tion. European Commission approval for marketing in 27
EU countries was finally granted on February 17th, 2012.
Despite this early approval for European marketing, it
is noteworthy that there exist important differences in
market access throughout the 27 EU countries. In fact,
each country needs additional time to obtain reimburse-
ment from its own national drug agency, which depends
on more or less structured internal processes.
Recent data show that there is a broad range of accessi-
bility times: in particular, the Patients W.A.I.T. (Waiting to
Access Innovative Therapies) Indicator 2010 Report for
new medicines in the period between 1 January 2007 and
31 December 2009 based on EFPIA’s database shows that
average time elapsing between the date of first valid EU
market authorization and the accessibility date (i.e. date of
completion of pricing/reimbursement procedures) in 14
European countries varies from 88 (Austria) to 392 days
(Belgium) (not considering Germany and the UK). In Italy
this time is of 326 days [25].
The mutated-BRAF approach
In melanoma, vemurafenib represents the first drug of a
lineage exerting its antiproliferative activity through in-
hibition of a highly specific molecular target. First
results with other targeted BRAF inhibitors like dabra-
fenib (GSK2118436) have provided similar dramatic
results, with a similar profile of toxicity, thus comfort-
ing both relevance and robustness of the approach
aimed at inhibiting the mutated BRAF.
In particular, the response rates reported in a phase I
study with dabrafenib was about 60 % in melanoma
patients carrying the BRAF-V600E/K mutation [26]. The
phase II study showed an overall response rate of 59 %
and a PFS of 27.4 weeks in the BRAF-V600E mutated
population [27]. A Phase III study comparing the activityof dabrafenib with dacarbazine is currently ongoing: the
sample population will include 200 BRAF-V600E
mutated patients and the primary endpoint will be the
PFS, since the study will allow crossover (NCT01227889).
RAF265 is a BRAF-V600E and VEGFR2 inhibitor that
showed dose-dependent inhibition of tumor growth and
tumor regression in xenografts presenting BRAF-V600E
mutant cells. The first clinical experience was reported
in 2011. In a phase I study of 71 evaluable patients re-
sponse rates were disappointing: 16 % in patients with
BRAF mutations and 13 % in patients with wild-type
BRAF [28].
LGX818 in another BRAF inhibitor selective for the
BRAF-V600E mutation which is under phase I investiga-
tion (NCT01436656).
BRAFV600 mutation test: who should do this?
A BRAFV600 mutation test is necessary to determine if
a patient might be a candidate for vemurafenib therapy.
Together with the BRAF inhibitor, a mutation test has
been approved by FDA, which is able to detect V600E,
V600K and V600D substitutions more sensitively than
Sanger sequencing [29]. In many countries, strategies
dedicated to tumor typing and based on different techni-
ques have been settled. In any case quality control is
warranted.
Taking into account the evidence from clinical trials,
we strongly support the need to screen for the BRAF-
V600 mutation all patients with advanced melanoma
(unresectable stage III and stage IV), who are most likely
to derive benefit from vemurafenib treatment, especially
when symptomatic with their disease. Patients with a
high risk for recurrence (stage IIIB and IIIC) are also
reasonable to consider for mutation screening.
The adjuvant role of this agent is being studied in the
BRIM-8 trial. This is a phase III, randomized, double-
blind, placebo-controlled study of vemurafenib adjuvant
therapy in patients with surgically-resected cutaneous
BRAF mutant melanoma at high risk for recurrence.
The role of vemurafenib and ipilimumab in the treatment
of advanced melanoma
The actual place of the novel anti-CTLA-4 mAb ipilimu-
mab [30,31] is obvious in non mutant BRAF patients, but is
still a matter in BRAF mutant patients which has shown an
impact directly on OS. Ipilimumab has a very different pro-
file from BRAF-inhibitors with a slow action and an impact
directly on OS, often without evidence of immediate re-
sponse. In clinical practice, it may seem relevant to initially
treat asymptomatic advanced stage IV M1a/b BRAF mutant
melanoma patients with high-dose IL-2 or ipilimumab. The
reasons for this lie in the mechanisms of action of immuno-
therapy and the singular durable benefit that is recorded
with mature trials of both of these immunotherapy agents,
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and (b) have a durable impact on OS often without an
acute influence upon tumor size and symptoms. However,
the median OS reached in phase II (15.9 months) and the
phase III study (13.2 months) with vemurafenib represent
the most favorable impact upon OS seen in melanoma
trials to date. The setting of metastatic melanoma and in
particular those patients with low tumor burden has been
recently studied by Amaravadi et al [32]. They showed that
the median survival of Phase I BRAF V600E melanoma
patients treated with vemurafenib was 16 months, and the
54 % and 44 % of patients were still alive at 1 and 2 years,
respectively. The recent results of BRIM2 study [22] are
consonant with this. Most important, patients with
>12 months’ PFS had a significantly lower baseline tumor
burden compared with patients with PFS <6 months, eval-
uated using RECIST. In fact, considering a baseline target
lesion cut-off value of 11.5 cm of diameter, in patients with
a target tumor burden< 11.5 cm the median PFS and OS
was of 16 and 27.1 months, respectively; while, in patients
with a target> 11.5 cm the PFS and OS was of 6.6 and
12.0 months, respectively [32]. This finding suggests an im-
pact of vemurafenib in the patients with a low tumor bur-
den. This may provide part of the rationale for the
evaluation of vemurafenib and BRAF inhibitors in meta-
static melanoma apart from symptomatic patients, as well
as for consideration of this agent in the adjuvant setting, as
a single agent.
B-raf inhibitors: pathways involved in drug resistance
Even if the majority of patients treated with vemurafenib
show a shrinkage of tumor lesions, soon after the first evi-
dence of objective response was observed with vemurafenib,
evidence of disease progression quickly manifested in some
patients. The range of response duration with this therapy
is quite broad [33].
There appear to be both MAPK pathway-dependent and
MAPK pathway-independent mechanisms by which tumors
can survive and adapt in the setting of BRAF inhibitor ther-
apy. In the majority of cases, there is biochemical evidence
of reactivation of the MAPK pathway: the appearance of
concomitant NRAS mutations; the appearance of a MEK
mutation has been described; increased expression of COT
kinase [34].
Additional mechanisms appear to be predominantly acti-
vated by signaling to the PI3K pathway. These include upre-
gulation of platelet-derived growth factor (PDGF) receptor
and insulin-like growth factor (IGF) receptor [35].
Considering these evidences of disease progression
after vemurafenib treatment, clinical trials have already
started to test combination or succession of therapies in
melanoma patients with high risk for recurrence or who
have progressed [36,37]. For instance, combination with
a MEK inhibitor has been hypothesized to prolong PFSand appears to prevent the emergence of skin toxicities
on the basis of experimental and first clinical results.
B-raf inhibitors beyond progression
For a subset of patients with disease progression, con-
tinuation of vemurafenib treatment is potentially benefi-
cial after local therapy (surgery or radiotherapy). Kim
et al. pointed out pattern and outcome of disease pro-
gression from the phase I vemurafenib clinical trial [33].
Common sites of disease progression were: skin/soft tis-
sue (44 % of all 48 pts); nodes (27 %); brain/CNS (25 %);
lungs (19 %); liver (15 %); bone, GI (10 %). Among 42
pts with PD, 19 (45 %) progressed only in new sites, 8
(19 %) in the brain only and 11 (26 %) in both new and
original sites. Among 18 pts who continued vemurafenib
>30 days after a local alternative therapy of a site of dis-
ease progression, a median overall survival exceeds
15.5 months from initiation of BRAF inhibitor therapy.
Median treatment duration beyond initial disease pro-
gression was 3.6 months (range, 1.1–9.9) and median
overall survival from the time of initial disease progres-
sion was not reached (median follow-up 6.0 months).
For patients who did not continue treatment, median
overall survival from the time of disease progression was
1.4 months. Adverse events during continued dosing in
these patients were similar to those observed before dis-
ease progression [33]. Obviously, these results require
prospective assessment in trials where additional therap-
ies are added in proscribed time-frames.
B-raf inhibitors in combination trials
A clinical phase I/II trial has been designed to evaluate the
safety, tolerability, and efficacy of vemurafenib in combin-
ation with the Cytotoxic T Lymphocyte Antigen 4 (CTLA-
4) inhibitor mAb ipilimumab [37]. This kind of combined
treatment merges target therapy and immunotherapy
approaches. The two drugs show different mechanisms of
action, with ipilimumab (first- and second-line treatment in
USA, second-line treatment in Europe to treat patients with
late-stage metastatic unresectable melanoma) sustaining an
active immune response. B-Raf inhibitors and ipilimumab
also show a different pattern of action: while vemurafenib
has been demonstrated to have quick action, rapid meta-
bolic shutdown, but disease progression after a median of
6–8 months, the mAb shares a slow action with the ability
to make the disease chronic.
Another kind of approach is being tested in the BRIM-7
trial [37]. This phase Ib, dose-escalation study aims at
evaluating the safety, tolerability and pharmacokinetics of
vemurafenib in combination with GDC-0973 in patients
with BRAFV600E positive metastatic melanoma who have
progressed after treatment with vemurafenib alone. GDC-
0973 is a potent and highly selective inhibitor of MEK1/2,
downstream targets of BRAF. The rationale underlying this
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additive or possibly synergistic effects upon PFS; the second
concerns the possibility avoidance of toxicities that may ac-
company the stimulation of the MEK pathway when BRAF
inhibitors are used as single agents. This may prove to be a
basis for the cSCCs and keratoacanthomas reported in most
trials of BRAF inhibitors alone. Co-treatment with a MEK
inhibitor is a rational approach to attenuating the skin toxi-
cities of RAF inhibitor treatment and may also enhance the
antitumor effects of RAF inhibitors by synergistically sup-
pressing ERK pathway activity [38]. Recent phase I and II
trials showed that this kind of approach is safe and able to
lower the toxicity of either agent alone [39].BRAF inhibitor toxicities
Vemurafenib was well tolerated in all the clinical trials
so far completed. In the BRIM-3 trial, the incidence of
grade 1 to 2 and grade 3 to 4 adverse events was similar
to those from prior studies. Common toxicities observed
with vemurafenib include arthralgia, photosensitivity,
rash, pruritus, alopecia, nausea, diarrhea and fatigue [24].
Sixty-one patients (18 %) had development of cSCC or
keratoacanthoma. cSCCs and keratoacanthomas have
previously been detected in patients treated with sorafenib,
indicating a common mechanism in developing these ad-
verse events. No metastatic evolution of RAF inhibitor-
induced cSCCs has ever been reported.
The appearance of keratoacanthomas and cSCCs early
in the course of treatment is speculated to involve the acti-
vating effect of vemurafenib on preneoplastic cells in
which wild-type BRAF is further primed by upstream
pathway activation. However, all these observed skin toxi-
cities showed low metastatic potential, often regress spon-
taneously and are easily cured by surgical resection and/or
destructive methods (cryotherapy or electrodessication/
curettage) [38]. Several investigators have shown that
vemurafenib and other inhibitors of RAF kinases can po-
tentiate the activity of the MAPK pathway in cells with
wild-type BRAF [40-42].
Dabrafenib has a similar safety profile of the vemurafenib
[27]. However, vemurafenib was typically associated with
photosensitivity (in approximately 30 % of treated patients
BRIM3), whereas pyrexia (24 %) was mainly reported in
dabrafenib treatment.
There is a concern about potential induction of new pri-
mary melanomas using BRAF inhibitors, but so far this risk
is easily manageable in patients under surveillance, and has
a low weight into the treatment of the metastatic disease.BRAF inhibitors: possible role in the BRAF-V600K patient
population?
Even if vemurafenib has been extensively tested on mel-
anoma patients expressing the BRAFV600E mutatedform, it has also been demonstrated to be effective in
inhibiting the V600K mutated form.
In fact, in vitro studies on melanoma cells isolated from
primary or metastatic lesions showed that vemurafenib was
also able to suppress the V600KBRAF activity [43]. Beside
preclinical data demonstrating similar kinase activity of the
V600K and V600E mutations, clear evidences of clinical ac-
tivity of vemurafenib in patients with documented V600K
mutation suggest that these patients are eligible to vemura-
fenib treatment too [44].
On behalf of the latter evidences, it is noteworthy that
EMA’s CHMP positive opinion was not restricted to the
V600E mutations like FDA approval, but included all
kind of V600 mutations, comprising the less frequent
ones.
In this sense, dabrafenib was also given for treatment
of BRAF-V600K mutated patient (n = 16) in the phase II
study [27], with an overall response rate of 13 % (and an-
other 44 % with SD) and a PFS of 19.7 weeks, which
demonstrated an impact even in this population.The role of BRAF inhibitors in brain metastases
Brain metastases (BM) are the most frequent intracranial
tumors in adults and are up to ten fold more common
than primary brain neoplasms. They are manifestations/
complications of systemic tumors and in contrast to pri-
mary brain tumors do not constitute a separate disease
entity [45]. Melanoma is the third most frequent primary
tumor type in terms of brain metastasis, after lung and
renal cell cancers [46]. BM are diagnosed in up to 10 %
of melanoma patients during their disease course and
BM are found at autopsy in up to 73 % of patients who
died from disseminated cutaneous melanoma [47].
Patients with active BM have been excluded from prior
and current vemurafenib trials. However, there are favorable
preliminary efficacy data on other inhibitors of mutant
BRAF, in patients with brain-metastatic melanoma [48] and
a single-arm, phase II, multicenter study, evaluating efficacy
and safety of vemurafenib in patients with brain-metastatic
melanoma has been initiated (NCT01378975) [49]. Such
systemic approaches are very promising, as expression of
the therapeutic target (BRAF V600E-mutant protein) has
been shown to be homogenous throughout the tumor tissue
and to be consistent between different tumor manifestations
in individual patients [50].
Analogously, dabrafenib showed good efficacy on brain
metastases [26,51].Conclusions
Melanoma has historically had a poor prognosis because
of lack of responsiveness to traditional chemotherapeu-
tics as far as the finding that around one half harbors an
activating mutation in BRAF leads to a challenging but
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therapy.
This approach proved to be favorable since the first
preclinic studies, whose results were then confirmed in
clinical trials: vemurafenib represents an excellent model
of anticancer targeted therapy, showing both unprece-
dented clinical activity and a good safety profile.
A diagnostic test to identify mutant BRAF melanoma
patients that can receive benefit from vemurafenib treat-
ment makes vemurafenib the first personalized targeted
therapy in metastatic melanoma, able to recognize
patients for whom treatment will more likely than not
improve progression free and overall survival outcomes,
with a tolerable safety profile.
Other drugs are currently under development and
evaluation with the same target, like dabrafenib, or add-
itional targets into the downstream pathway, and the
results strongly confirm the concept firstly demonstrated
for vemurafenib. As a consequence, future improvements
of this targeted and personalized approaches are
expected from ongoing clinical trials aiming at potentiate
the activity of BRAF inhibitors through combination
with other molecules, both immune-based and targeting
the downstream pathway. These combination therapies
also aim at lowering the observed skin toxicities.Competing interests
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